ASX:VBS

Vectus Biosystems Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive VBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Vectus Biosystems and its competitors with MarketBeat's FREE daily newsletter.

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:VBS
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.vectusbiosystems.com.au
Phone: 61 2 9662 4144
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $81,590.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A($0.09) per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.61
Quick Ratio: 3.52

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.88 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vectus Biosystems.

4.4 Community Rank

Outperform Votes
Vectus Biosystems has received 2 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vectus Biosystems has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vectus Biosystems has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vectus Biosystems and other stocks. Vote “Outperform” if you believe VBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vectus Biosystems does not currently pay a dividend.
Dividend Growth
Vectus Biosystems does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vectus Biosystems insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Vectus Biosystems (ASX:VBS) Frequently Asked Questions

What stocks does MarketBeat like better than Vectus Biosystems?: Wall Street analysts have given Vectus Biosystems a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vectus Biosystems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Vectus Biosystems' key executives?: Vectus Biosystems' management team includes the following people:
Dr. Karen Annette Duggan, CEO & Exec. Director
Mr. Robert John Waring BEc, CA, FCIS, FFin, FAICD, Company Sec.
Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC, Consultant
Who are some of Vectus Biosystems' key competitors?: Some companies that are related to Vectus Biosystems include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of VBS's competitors.
What is Vectus Biosystems' stock symbol?: Vectus Biosystems trades on the ASX under the ticker symbol "VBS."
How much money does Vectus Biosystems make?: Vectus Biosystems has a market capitalization of $0.00 and generates $81,590.00 in revenue each year.
What is Vectus Biosystems' official website?: The official website for Vectus Biosystems is www.vectusbiosystems.com.au.
How can I contact Vectus Biosystems?: The company can be reached via phone at 61 2 9662 4144.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.